LIMN stock forecast, quote, news & analysis
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company engaged in developing cancer therapies and treatments... Show more
Why Liminatus Pharma (LIMN) Stock Is Down -27% in the Last 30 Days
Key Takeaways
- Liminatus Pharma shares declined roughly 27% over the trailing 30 days, sliding from about $4.03 to $2.94 as selling pressure persisted in a low-float, pre-clinical biotech.
- The pullback extended a longer multi-month downtrend, with the stock trading near $6 in early July and around $5 in early August before breaking below $3.
- Nasdaq listing-compliance news provided only temporary support, as shares resumed their slide shortly after the company confirmed it had regained the minimum bid price rule.
- Lingering dilution concerns tied to a pending InnocsAI merger, a large warrant overhang, and related-party financing remain key overhangs on investor sentiment.
- As a pre-clinical-stage company with no product revenue, Liminatus depends heavily on financing and clinical milestones for its IBA101 and IBC101 oncology programs.
- Get more detail on Price Targets, Earnings, and Forecast for LIMN to track the company's financial picture.
- Explore Trending AI Robots to see curated, top-performing AI trading bots.
Liminatus Pharma (LIMN) Company Overview and Market Position
Liminatus Pharma, Inc. is a pre-clinical to early-clinical stage biopharmaceutical company focused on immune-modulating cancer therapies. Its lead asset is IBA101, a next-generation humanized anti-CD47 monoclonal antibody engineered to block the "don't-eat-me" signal that tumors use to evade immune surveillance, with lung cancer as the initial clinical focus. The company is also advancing IBC101, a CD19xCD22 bivalent CAR-T candidate for B-cell malignancies, through its pending merger with InnocsAI. Founded in 2018 and based in California, Liminatus trades on the Nasdaq Global Market and operates with a micro-cap market value, no product revenue, and a development pipeline that remains dependent on external financing and clinical execution.
Liminatus Pharma (LIMN) Stock Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, LIMN declined approximately 27%, falling from about $4.03 to $2.94. The move was not driven by a single dramatic event but rather by persistent, low-liquidity selling in a thinly traded micro-cap, with average daily volume in the tens of thousands of shares and a market capitalization of roughly $4 million. The stock touched an intraday high near $4.48 during the period before giving back those gains and sliding to the low end of its recent range.
The quarterly trend is more pronounced. Shares traded near $6 in early July and approximately $5 in early August before the steady decline that brought the stock below $3, representing a decline of roughly 40% to 50% depending on the exact reference point. The overall trajectory has been consistently downward, with brief rallies failing to hold above key levels.
What Drove LIMN Stock Price in the Last 30 Days
The 30-day decline reflects a combination of structural pressures rather than any single negative announcement. In late September, the company confirmed it had regained compliance with Nasdaq's minimum bid price rule after completing a 1-for-50 reverse stock split, yet the positive news failed to sustain buying interest. The shares briefly rallied before renewed selling resumed.
The most persistent weight on sentiment is dilution. A pending, related-party merger with InnocsAI could issue approximately 1.6 billion new shares, a multiple of the company's current float, while a substantial warrant overhang remains registered for resale. Combined with a history of capital-raising events, including a $4 million public offering earlier in 2026, investors have priced in the risk of further share issuance. With no revenue and deeply negative earnings per share, the stock remains highly sensitive to financing headlines and thin order books.
What Drove LIMN Stock Performance Over the Last Quarter
The quarterly decline has been shaped primarily by capital-structure stress rather than clinical setbacks. In May, Liminatus disclosed a Nasdaq delisting notification, prompting a transfer to the Nasdaq Capital Market and, in August, a 1-for-50 reverse stock split designed to restore the minimum bid price. The company subsequently regained compliance, but the episode underscored the fragility of a micro-cap listing under financing strain.
Operationally, Liminatus made progress by engaging Synex Consulting to support Phase 1/2a development of its IBC101 CAR-T program and by amending the InnocsAI merger agreement to expand its cell-therapy pipeline. However, the overriding narrative has been dilution risk: the proposed merger's share issuance, the warrant overhang, and repeated financing rounds have outweighed pipeline milestones in investor minds, keeping the stock in a sustained downtrend.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots drawn from a broader universe of hundreds of bots trading thousands of tickers. Only the top-performing and most relevant bots appear in this section, which means the list reflects recent performance and activity rather than the full catalog. The bots vary in strategy, timeframe, and performance metrics, so investors can compare approaches that range from short-term momentum to longer-horizon models. Browsing the section offers a useful way to observe how automated, rules-based systems are navigating current market conditions across different stocks.
LIMN Stock Forecast Drivers: What Investors Should Watch Next
Investors tracking LIMN should monitor several near-term catalysts. The company's upcoming quarterly results will offer fresh visibility into cash position, operating expenses, and financing needs. The proposed InnocsAI merger, with an outside closing date at the end of 2026, is a pivotal event because its share-issuance structure could materially reshape the equity base. On the pipeline side, regulatory submissions for IBA101 and the planned initiation of its Phase 1 trial, as well as progress on the IBC101 CAR-T program, represent the primary scientific milestones. Finally, continued Nasdaq minimum-bid compliance, the warrant overhang, and any additional capital raises will be central to how the stock trades. These factors carry substantial uncertainty, and the stock remains speculative.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
LIMN sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for LIMN moved below the 200-day moving average on October 27, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LIMN as a result. In 34 of 107 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 32%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LIMN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 73%.
The Aroon Indicator for LIMN entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 29 of 61 cases where LIMN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 48%.
Following a +9.05% 3-day Advance, the price is estimated to grow further. Considering data from situations where LIMN advanced for three days, in 53 of 90 cases, the price rose further within the following month. The odds of a continued upward trend are 59%.
LIMN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.349) is normal, around the industry mean (3.498). P/E Ratio (-0.106) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. LIMN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LIMN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology